Insufficient exclusion of infectious and biofilm-related complications in reported tirzepatide-associated filler nodules Authors: Poramate Pitak-Arnnop Published: 2026 To the Editor: The proposed inflammatory reaction to tirzepatide associated with recurrent facial nodules after filler injections reported by Luke et al1 is intriguing. However, no definitive microbiological or histopathological investigations were performed. The recurrent and migratory “on-off” swelling across multiple injection sites is not specific to a sterile inflammatory drug reaction. This presentation is also compatible with indolent infectious processes, including biofilm-associated infections and atypical organisms such as nontuberculous mycobacteria or low-grade staphylococcal infection—all recognized complications of dermal fillers and injectable procedures. The absence of a biopsy, tissue culture, or aspirate analysis substantially weakens causal inference and means that infection cannot be ruled out with sufficient certainty. This issue is particularly relevant because repeated esthetic injections were administered at different sites and by different practitioners, which increases susceptibility to subclinical infection. Additionally, compounded preparations introduce uncertainty regarding sterility and contamination risk. Although tirzepatide is not considered immunosuppressive, infectious complications have been reported nonetheless. The reported response to doxycycline and isotretinoin is clinically informative but nonspecific. Doxycycline has antimicrobial, anti-inflammatory, and antibiofilm properties, and isotretinoin has broad immunomodulatory effects, including cytokine downregulation and modulation of innate immunity. Consequently, improvement with these agents does not distinguish between infectious and inflammatory etiologies. Therefore, infectious causes should remain central to the differential diagnosis, and future reports should include histological and microbiological confirmation before attributing causality to tirzepatide or other systemic agents. Conflicts of interest None disclosed. Footnotes Funding sources: None. IRB approval status: Not applicable. Reference